GiT Updates and More
Kanalga Telegramāda oātish
Gi doctor with interests in endoscopy, gut health, liver & medicine in general.
Ko'proq ko'rsatish5 323
Obunachilar
+1624 soatlar
+307 kun
+10130 kun
Postlar arxiv
5 321
Performance measures for endoscopic ultrasound: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiativeā Update 2025
5 321
Non-Ā invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring.
BMJ 2025
5 321
Estimates of global and regional prevalence of Helicobacter pylori
infection among individuals with obesity: a systematic review
and metaāanalysis
5 321
Potassium-competitive acid
blockers ( PCABs ) for the management of Gastroesophageal reflux disease
5 321
Acute-on-chronic liver failure: pathophysiological mechanisms and clinical management
5 321
ā³ļø Extra-hepatic Manifestations of Chronic HCV Infection
1. Mixed Cryoglobulinemia / Vasculitis
2. Non-Hodgkin B-cell Lymphoma
3. Insulin resistance / Type 2 Diabetes Mellitus
4. Membranoproliferative Glomerulonephritis
5. SjÓ§grenās syndrome and Sicca symptoms
6. Autoimmune thyroid disease
7. Porphyria cutanea tarda
8.Lichen planus / skin disorders
9. Hematologic disorders (e.g., thrombocytopenia)
10. Neuropathy / neurological disorders
11. Cardiovascular disease associations
12. Other autoimmune or rheumatologic conditions
13. Metabolic alterations (lipid abnormalities)
ā³ļø Extra-hepatic Manifestations of HBV Infection
1. Serum-sicknessālike syndrome
2. Polyarteritis nodosa (PAN)
3. Membranous Glomerulonephritis/nephropathy
4. Cryoglobulinemic vasculitis (less consistent)
5. Non-rheumatoid arthritis / polyarthritis
6. Non-Hodgkin lymphoma (less common)
7. Aplastic anemia / hematologic abnormalities
8. Papular acrodermatitis (Gianotti-Crosti syndrome)
5 321
Real-World Indirect Treatment Comparison of Terlipressin vs Midodrine Plus Octreotide in Hepatorenal Syndrome-Acute Kidney Injury. (PDF š)
ā³ļø Conclusion: HRS-AKI treatment and outcomes differ between the United Kingdom and the United States, attributed to the historical standard of care MO in the United States. In adjusted analyses, real-world use of terlipressin was more effective than MO at improving kidney function and achieving HRS-AKI reversal.
5 321
ā³ļø #Pearls: HIV-negative wife should receive daily oral TDF/FTC PrEP starting at least 7 days before exposure and continued until the HIV-positive partner has sustained viral suppression for 6 months, then stopped 28 days after last exposure. Neonatal prophylaxis with zidovudine should be initiated within 6ā12 hours of birth and continued for 4ā6 weeks if the mother is HIV-positive.
5 321
Propranolol versus endoscopic variceal ligation for primary prophylaxis of esophageal varices in cirrhosis: a systematic review
and metaāanalysis of randomized controlled trials
š„Conclusion: EVL was superior in preventing esophageal variceal bleeding. Such results suggest that not all NSBBs provide equivalent efficacy in primary prophylaxis, reinforcing the need for further studies to confirm these findings.
5 321
Early infliximab (IFX) levels and clearance predict outcomes after IFX rescue in acute severe ulcerative colitis:
Results from PREDICT-UC
AGA Gastroenterology 2026
5 321
Early infliximab (IFX) levels and clearance predict outcomes after IFX rescue in acute severe ulcerative colitis:
Results from PREDICT-UC
PDF š
AGA Gastroenterology 2026
5 321
š„ Hot From the Press | Clinical Pearl
Acute Severe UC: Early infliximab exposure matters.
š¹ Day-3 infliximab ā¤57.9 µg/mL predicts:
š¤ Day-14 failure
š¤3-month colectomy
š¹ High infliximab clearance drives non-response ā but can be overcome with intensified dosing (10 mg/kg).
ā ļø Limitations:
⢠Real-world TDM turnaround may be delayed
⢠Clearance not easily calculated at bedside
⢠Observational PK analysis
PDF š
